Welcome to Interconnect®
At Interconnect, we provide the very best in personalized treatment support. Our dedicated Care Coordinators work with people who have been prescribed an Intercept treatment and their healthcare providers.
At Interconnect, we provide the very best in personalized treatment support. Our dedicated Care Coordinators work with people who have been prescribed an Intercept treatment and their healthcare providers.
You are now leaving Interconnect
Any information you provide after you leave this site and enter another site will be subject to the other website’s privacy policy and terms and conditions. Interconnect is not responsible for the use, security, or disclosure of any information you may provide to another site.
Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for the treatment of primary biliary cholangitis (PBC), a rare, progressive liver disease.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or call 1-844-782-4278. Patients should talk to their healthcare professionals and may also contact Intercept's Patient Support Services (Interconnect) at 1-844-622-4278.
For all other inquiries please visit: https://www.interceptpharma.com/
Please click here for Full Prescribing Information and Medication Guide for OCALIVA.